SEB trastuzumab passes first two
pre-clinical tests

The first two facets of pre-clinical trials involving PlantForm’s plant-produced trastuzumab are complete and the results are promising, says Dr. Michael D. McLean, Director of Research.

Safety and toxicology studies designed to assess the maximum tolerated dose of subsequent-entry-biologic (SEB) trastuzumab showed it was tolerated as well as the commercial antibody (Herceptin®) — with no ill effects in mice — at doses that were the equivalent of 25 to 50 times higher than the weekly dosage amount for humans.

Pharmacokinetic studies showed that PlantForm’s SEB trastuzumab and the commercial antibody had similar blood circulatory residence times.
 
“We’ve produced the antibody, injected it in mice, and shown that our process does not isolate any potentially adverse substances from plants that might cause ill effects,” McLean said. “We’ve also demonstrated that our antibody has similar blood circulatory residence time compared to the commercial antibody.”
 
In vitro studies, published in the Journal of Agricultural and Food Chemistry, have shown that PlantForm’s SEB trastuzumab effectively inhibits the growth of HER2-positive cancer cells and has the same activity as the commercial antibody.

Efficacy tests on breast cancer tumors in a mouse model are now under way.

Landmark engaged to obtain U.S. equity financing
PlantForm Corporation has engaged Landmark Capital Corporation as a strategic advisor in conjunction with the company’s $20-million equity financing to develop and market its plant-based technology platform for ultra-low-cost therapeutic antibody drugs.

Landmark Capital is a boutique investment bank based in Greenwich, CT, which will advise PlantForm and identify sources of institutional equity for the company.

The engagement is exclusive to the United States and includes PlantForm’s participation in theLandmark Venture Forum in Greenwich, CT on Sept. 22 and Landmark’s ‘Investing for Cures’ conference on Nov. 9 in New York City.

Read full news release.

David Cayea named Director of International Relations & Business Development
PlantForm is pleased to announce the appointment of David Cayea as Director of International Relations & Business Development. He will be responsible for advancing the company’s strategic growth strategy by developing and fostering global partnerships. Cayea has extensive business management experience in Europe, Asia and North America, most recently as the founder and CEO of North American Safety Consultants, based in Abu Dhabi.


Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter and LinkedIn:
                        
Fall 2011
Rights Offering
PlantForm is offering to current shareholders an opportunity to purchase additional shares at $0.75 per share. The minimum subscription is $25,000. The closing date for the transaction is Tuesday, Sept. 20.

Funds raised will be used as general working capital for ongoing research and development on a second product candidate and to complete the animal efficacy studies currently in progress on SEB trastuzumab for breast cancer.

For more information, please contact Don Stewart, President and CEO, or Ron Hosking, CFO.

Upcoming Events

AGM Sept. 20
PlantForm’s annual general meeting takes place Tuesday, Sept. 20 at 10:30 a.m. at 1920 Yonge St., Suite 200, Toronto, M4S 3E2.

Please email your intent to attend (and your proxy form if not attending) to plantform@gmail.com or fax to: (416) 572-7501.

~~~~~~~
PlantForm will be presenting at the following events: ~~~~~~~
Sarnia office opens
PlantForm has opened an office in the University of Western Ontario Research and Development Park (Sarnia-Lambton Campus).

Address:
1086 Modeland Road
Sarnia, Ontario N7S 6L2
Phone: (519) 333-6736
Fax: (519) 333-6735


Management Team

Don Stewart, PhD
President & CEO

Ron Hosking, CA
Chief Financial Officer

Chris Hall, PhD
Chief Scientific Officer
PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
M4S 3E2  CANADA		 For more information, contact:
Don Stewart
President & CEO
416-452-7242